SEARCH

SEARCH BY CITATION

References

  • 1
    Ellerin T, Hurtado R, Lockamn S, Baden L. Infections and anti-tumour necrosis factor alpha therapy. Arthritis Rheum. 2003; 48: 301322.
  • 2
    Walsh MJ, Vanags DM, Clouston AD et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004; 39: 12308.
  • 3
    Pol S, Zylberberg H, Fontaine H, Brechot C. Treatment of chronic hepatitis C in special groups. J. Hepatol. 1999; 31 (Suppl. 1): 2059.
  • 4
    Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 2001; 19: 6591.
  • 5
    Herbein G, O’Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc. Soc. Exp. Biol. Med. 2000; 223: 24157.
  • 6
    Kasahara S, Ando K, Saito K et al. Lack of tumour necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J. Virol. 2003; 77: 246976.
  • 7
    Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 100922.
  • 8
    Ahmed A, Keeffe E. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 1999; 94: 24951.
    Direct Link:
  • 9
    Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000; 62: 299307.
  • 10
    Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata El. Severe hepatitis related to chemotherapy in Hepatitis B virus carriers with haematological malignancies. Survey in Japan, 1987–1991. Cancer 1996; 78: 221015.
  • 11
    Kumagai K, Tagaki T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol. 1997; 8 (Suppl. 1): S1079.
  • 12
    Angus PW. Review: hepatitis B and liver transplantation. J. Gastroenterol. Hepatol. 1997; 12: 21723.
  • 13
    Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000; 6: 42933.
  • 14
    Ahmed A, Keefe E. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 1999; 94: 24951.
    Direct Link:
  • 15
    Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Ann. Oncol. 1998; 9: 3857.
  • 16
    Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J. Antimicrob. Chemother. 2005; 55: 82831.
  • 17
    Idilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J. Viral Hepat. 2004; 11: 1417.
  • 18
    Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann. Hematol. 2004; 83: 2705.
  • 19
    Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 202.
  • 20
    Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT. Biomedicines to reduce inflammation but not viral load in chronic HCV: what’s the sense? Trends Biotechnol. 2004; 22: 51723.
  • 21
    Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol. Cell Biol. 2001; 79: 51536.
    Direct Link:
  • 22
    Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83: 122430.
  • 23
    Faggioli P, De Paschale M, Tocci A et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica 1997; 82: 3842.
  • 24
    Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 1997; 26: 15.
  • 25
    Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 1996; 334: 81520.
  • 26
    Pavli P, Bayliss GJ, Dent OF, Lunzer MR. The prevalence of serological markers for hepatitis B virus infection in Australian Naval personnel. Med. J. Aust. 1989; 151: 745.
  • 27
    O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust. N. Z. J. Public Health 2004; 28: 21216.
  • 28
    Amin J, Gidding H, Gilbert G et al. Hepatitis C prevalence—a nationwide serosurvey. Commun. Dis. Intel. 2004; 28: 51721.
  • 29
    Biancone L, Pavia M, Del Vecchio Blanco G et al. Hepatitis B and C virus infection in Crohn’s disease. Inflamm. Bowel Dis. 2001; 7: 28794.
  • 30
    Longo F, Hebuterne X, Tran A et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol. Clin. Biol. 2000; 24: 7781.
  • 31
    Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53: 13635.
  • 32
    Ueno Y, Tanaka S, Shimamoto M et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig. Dis. Sci. 2005; 50: 1636.
  • 33
    Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, De Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm. Bowel Dis. 2004; 10: 7012.
  • 34
    Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann. Rheum. Dis. 2005; 64: 7889.
  • 35
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis. 2003; 62: 6867.
  • 36
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J. Rheum. 2003; 30: 16245.
  • 37
    Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur. J. Gastroenterol. Hepatol 2001; 13: 1912.
  • 38
    Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am. J. Gastroenterol. 2003; 98: 5045.
    Direct Link:
  • 39
    Parke FA, Reveille JD. Anti-tumour necrosis factor agents for RA in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004; 51: 8004.
  • 40
    Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J. Rheum. 2004; 31: 1079.
  • 41
    Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann. Rheum. Dis. 2003; 62: 107882.